BioLineRx rises on ASH BL-8040 poster presentation


Shares of BioLineRx (BLRX) trade 12% higher in premarket action.

Data presented at ASH show BL-8040 "is efficient in inducing the death of AML cancer cells both in vitro and in a humanized mouse model."

Here's CEO Kinneret Savitsky: "The results presented ... show that BL-8040 is highly effective in directly inducing AML cell death and in augmenting the effects of other drugs, resulting in an exceptionally high percentage of cell growth inhibition and death."

The company says "synergistic effects" were observed when BL-8040 was combined with quizartinib. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs